https://lifestyle.nblaz.com/story/157885/culp-dental-welcomes-dr-kimberely-helton-to-its-growing-family-of-care/ 2026-05-31T22:21:22+00:00 https://lifestyle.nblaz.com/story/157886/vrrm-investors-have-opportunity-to-join-verra-mobility-corporation-fraud-investigation-with-the-schall-law-firm/ 2026-05-31T22:37:21+00:00 https://lifestyle.nblaz.com/story/157887/goss-investors-have-opportunity-to-lead-gossamer-bio-inc-securities-fraud-lawsuit-with-the-schall-law-firm-17/ 2026-05-31T23:25:18+00:00 https://lifestyle.nblaz.com/story/157888/scripps-pulls-54-local-stations-from-directv-after-seeking-record-retransmission-consent-rates/ 2026-05-31T23:41:37+00:00 https://lifestyle.nblaz.com/story/157889/faraday-future-founder-and-global-ceo-yt-jia-shares-weekly-investor-update-total-sales-and-shipments-of-eai-robots-reached-69-units-in-may-a-new-record-exceeding-the-combined-total-for-the-months-o/ 2026-05-31T23:41:38+00:00 https://lifestyle.nblaz.com/story/157890/ascentage-pharma-presents-its-first-dataset-on-mdm2-p53-inhibitor-alrizomadlin-apg-115-in-pediatric-solid-tumors-at-asco-2026/ 2026-05-31T23:57:19+00:00 https://lifestyle.nblaz.com/story/157891/ascentage-pharma-presents-updated-clinical-data-for-olverembatinib-as-second-line-therapy-in-cml-cp-at-asco-2026/ 2026-05-31T23:57:19+00:00 https://lifestyle.nblaz.com/story/157892/ascentage-pharma-presents-data-on-olverembatinib-in-cml-lbp-and-ph-bcp-all-at-asco-2026/ 2026-05-31T23:57:19+00:00 https://lifestyle.nblaz.com/story/157893/tiumbio-to-present-phase-2a-interim-data-highlighting-differentiated-clinical-profile-for-tosposertibtu2218-plus-pembrolizumab-in-first-line-r-m-hnscc-at-asco-2026/ 2026-05-31T23:57:20+00:00 https://lifestyle.nblaz.com/story/157894/briacell-therapeutics-announces-pricing-of-offering/ 2026-06-01T00:12:25+00:00 https://lifestyle.nblaz.com/story/157895/immvira-reports-100-complete-response-rate-at-9-months-in-bladder-carcinoma-in-situ-with-mvr-t3011-at-asco/ 2026-06-01T00:12:26+00:00 https://lifestyle.nblaz.com/story/157896/d3-bio-presents-first-line-data-for-elisrasib-d3s-001-at-asco-2026-next-generation-kras-g12c-inhibitor-shows-landmark-efficacy-in-untreated-nsclc/ 2026-06-01T00:12:27+00:00 https://lifestyle.nblaz.com/story/157897/2026-asco-innovent-presents-long-term-follow-up-results-from-the-poc-study-of-ibi363-tak-928-pd-1-il-2%ce%b1-bias-bispecific-fusion-protein-showing-robust-survival-benefits-in-advanced-immunoth/ 2026-06-01T00:12:27+00:00 https://lifestyle.nblaz.com/story/157898/2026-asco-innovent-presents-preliminary-poc-data-of-ibi363-tak-928-pd-1-il-2%ce%b1-bias-bispecific-fusion-protein-in-first-line-advanced-nsclc/ 2026-06-01T00:12:28+00:00 https://lifestyle.nblaz.com/story/157899/new-taipei-city-showcases-smart-manufacturing-strength-at-automate-2026/ 2026-06-01T00:12:29+00:00 https://lifestyle.nblaz.com/story/157900/amd-bundles-carbice-ice-pad-with-ryzen-7-5800x3d/ 2026-06-01T00:12:30+00:00 https://lifestyle.nblaz.com/story/157901/microip-to-debut-ai-vehicle-system-business-group-and-edge-ai-innovations-at-computex-2026/ 2026-06-01T00:12:31+00:00 https://lifestyle.nblaz.com/story/157902/carbice-and-noctua-partner-to-bring-advanced-thermal-pad-technology-to-diy-pc-builders/ 2026-06-01T00:12:32+00:00 https://lifestyle.nblaz.com/story/157903/long-term-follow-up-results-of-carsgens-satri-cel-as-sequential-therapy-after-first-line-treatment-for-gastric-cancer-presented-at-the-2026-asco-annual-meeting/ 2026-06-01T00:28:55+00:00 https://lifestyle.nblaz.com/story/157904/asco-2026-cstone-presents-updated-clinical-data-for-cs2009-pd-1-vegf-ctla-4-trispecific-antibody-reinforcing-triple-target-synergy-and-delivering-strong-proof-of-concept/ 2026-06-01T00:28:56+00:00 https://lifestyle.nblaz.com/story/157905/bests-market-segment-report-japan-life-insurers-use-of-reinsurance-more-than-doubled-since-2020/ 2026-06-01T00:44:27+00:00